Skip to content

Virax Biolabs Group Limited

VRAX

CIK 0001885827

← back to feed
Revenue (TTM)
—
FY Mar 2025
Net Income (TTM)
−$6.07M
+10.0% YoY FY Mar 2025
EPS Diluted (TTM)
−$1.62
+51.8% YoY FY Mar 2025
Gross Margin
—
FY Mar 2025
Operating Margin
—
FY Mar 2025
Net Margin
—
FY Mar 2025
Free Cash Flow (TTM)
—
FY Mar 2025
Cash
$4.23M
FY Mar 2025
Total Debt
—
FY Mar 2025
Shares Outstanding
4.34M sh
FY Mar 2025

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings